|
adult |
16 |
|
female |
16 |
|
humans |
16 |
|
male |
16 |
|
middle aged |
16 |
|
chronic hepatitis b |
14 |
|
nafld |
14 |
|
aged |
12 |
|
hbv |
12 |
|
antiviral therapy |
11 |
|
entecavir |
11 |
|
hepatitis b virus |
10 |
|
antiviral |
9 |
|
hepatocellular carcinoma |
9 |
|
nash |
9 |
|
non-viral liver disease |
9 |
|
pre-s deletions |
9 |
|
tumorigenesis |
9 |
|
hbsag |
8 |
|
hla‐dp |
8 |
|
ifn‐γ pathway |
8 |
|
nephrotoxicity |
8 |
|
nucleoside analogues |
8 |
|
tenofovir |
8 |
|
cap |
7 |
|
carcinoma, hepatocellular - etiology |
7 |
|
colorectal cancer |
7 |
|
controlled attenuation parameter |
7 |
|
disease progression |
7 |
|
endocrinology |
7 |
|
epidemiology |
7 |
|
etv |
7 |
|
hepatitis b |
7 |
|
hepatitis b surface antigen |
7 |
|
lamivudine |
7 |
|
liver cirrhosis - etiology |
7 |
|
liver stiffness |
7 |
|
medical sciences |
7 |
|
natural history |
7 |
|
nucleos(t)ide analogue |
7 |
|
nucleoside analogue |
7 |
|
surface antigen |
7 |
|
adefovir |
6 |
|
aged, 80 and over |
6 |
|
alanine aminotransferase |
6 |
|
anti-bacterial agents - pharmacology |
6 |
|
biomarker |
6 |
|
cirrhosis |
6 |
|
drug resistance, viral |
6 |
|
genotype 1 |
6 |
|
genotype 6 |
6 |
|
gram-positive bacterial infections - epidemiology - microbiology - mortality - physiopathology |
6 |
|
hbeag |
6 |
|
hbv dna |
6 |
|
hepacivirus - classification - genetics - pathogenicity |
6 |
|
hepatitis b virus - drug effects |
6 |
|
hepatitis b(e) antigen |
6 |
|
hepatitis b, chronic - complications - drug therapy |
6 |
|
hepatitis c |
6 |
|
hepatitis c, chronic - complications - metabolism - virology |
6 |
|
hong kong - epidemiology |
6 |
|
host-pathogen interactions |
6 |
|
kinetics |
6 |
|
lamivudine - pharmacology - therapeutic use |
6 |
|
liver neoplasms - etiology |
6 |
|
m2bpgi |
6 |
|
microbial sensitivity tests |
6 |
|
mortality |
6 |
|
prognosis |
6 |
|
prospective studies |
6 |
|
retrospective studies |
6 |
|
reverse transcriptase inhibitors - therapeutic use |
6 |
|
risk factors |
6 |
|
shewanella - classification - drug effects - isolation & purification - pathogenicity |
6 |
|
time factors |
6 |
|
treatment outcome |
6 |
|
virus dna |
6 |
|
adenocarcinoma |
5 |
|
alanine transaminase - blood |
5 |
|
antiviral agents - administration and dosage - therapeutic use |
5 |
|
colonic neoplasms |
5 |
|
colonoscopy |
5 |
|
deep sequencing |
5 |
|
dna, viral - analysis |
5 |
|
freezing |
5 |
|
genotype |
5 |
|
guanine - administration and dosage - analogs and derivatives - therapeutic use |
5 |
|
hbeag seroconversion |
5 |
|
hcc |
5 |
|
hepatitis b core-related antigen |
5 |
|
hepatitis b surface antigens - blood |
5 |
|
hepatitis b surface antigens - blood - chemistry |
5 |
|
hepatitis b surface antigens - genetics |
5 |
|
hepatitis b virus - classification - genetics |
5 |
|
hepatitis b virus - genetics - immunology - isolation and purification |
5 |
|
hepatitis b virus - genetics - isolation and purification |
5 |
|
hepatitis b virus dna rebound |
5 |
|
hepatitis b, chronic - drug therapy - enzymology - immunology |
5 |
|
hepatitis b, chronic - drug therapy - virology |
5 |
|
hepatitis b, chronic - epidemiology - physiopathology - virology |
5 |
|
medical sciences - oncology |
5 |
|
medical sciences - urology and nephrology |
5 |
|
na therapy |
5 |
|
protein precursors - genetics |
5 |
|
protein stability |
5 |
|
quantitative |
5 |
|
quasispecies |
5 |
|
specimen handling - methods |
5 |
|
stopping |
5 |
|
treatment guidelines |
5 |
|
viral load |
5 |
|
13c-urea breath test |
4 |
|
adolescent |
4 |
|
amoxicillin - therapeutic use |
4 |
|
anti-bacterial agents - therapeutic use |
4 |
|
antibiotics |
4 |
|
bariatric surgery - mortality |
4 |
|
body mass index |
4 |
|
clarithromycin |
4 |
|
clarithromycin - therapeutic use |
4 |
|
diabetes mellitus, type 2 - prevention & control |
4 |
|
dialysis |
4 |
|
drug therapy, combination - methods |
4 |
|
empirical first-line eradication |
4 |
|
end stage renal disease |
4 |
|
fatty liver - surgery |
4 |
|
gastric balloon |
4 |
|
gastric bypass - statistics & numerical data |
4 |
|
gastroplasty - statistics & numerical data |
4 |
|
helicobacter infections - drug therapy |
4 |
|
helicobacter pylori |
4 |
|
helicobacter pylori - drug effects |
4 |
|
helicobacter pylori - treatment |
4 |
|
hepatitis b e antigen (hbeag) |
4 |
|
hepatitis b virus (hbv) dna |
4 |
|
hong kong |
4 |
|
kidney failure, chronic - therapy |
4 |
|
kidney transplantation |
4 |
|
levofloxacin |
4 |
|
long-term |
4 |
|
malnutrition - etiology |
4 |
|
obesity - surgery |
4 |
|
ofloxacin - therapeutic use |
4 |
|
omeprazole - therapeutic use |
4 |
|
peritoneal dialysis |
4 |
|
peritonitis |
4 |
|
renal dialysis - adverse effects |
4 |
|
superior mesenteric artery syndrome |
4 |
|
superior mesenteric artery syndrome - etiology - radiography - therapy |
4 |
|
weight loss - physiology |
4 |
|
antiviral agents - therapeutic use |
3 |
|
gastric cancer |
3 |
|
healthcare dataset |
3 |
|
hepacivirus - genetics |
3 |
|
hepatitis c, chronic - drug therapy - genetics - virology |
3 |
|
inflammatory bowel disease |
3 |
|
interleukins - genetics - therapeutic use |
3 |
|
polymorphism, single nucleotide |
3 |
|
hepatitis b, chronic - complications |
2 |
|
proportional hazards models |
2 |
|
roc curve |
2 |
|
5-羟色胺 |
1 |
|
5-羟色胺再摄取转运蛋白 |
1 |
|
antibody to hepatitis b core antigen |
1 |
|
antibody to tumor necrosis factor |
1 |
|
antigen cd20 |
1 |
|
hematopoietic stem cell transplantation |
1 |
|
occult |
1 |
|
rituximab |
1 |
|
溃疡性结肠炎 |
1 |
|
肠嗜铬细胞 |
1 |
|
色氨酸羟化酶1 |
1 |
